A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer.
The aim of this trial is to investigate whether pre-operative treatment with chemotherapy plus radiation therapy has a better outcome than chemotherapy alone in patients undergoing surgery for resectable gastric cancer.
Primary Sponsor
Collaborating Groups
TROG Cancer Research; Canadian Cancer Trial Group (CCTG); European Organisation for Research & Treatment of Cancer (EORTC); National Health and Medical Research Council Clinical Trials Centre (NHMRC CTC)
Accrual Target
570
Final Accrual
574
Expected Date of Accrual
31 December 2020
Closing Date of Accrual
May 2021
Trial Chairperson
Professor Trevor Leong, Peter MacCallum Cancer Centre, VIC
Trial Contact
topgear.study@sydney.edu.au
Related Post
TROG welcomes new Board members and President-Elect
LATEST NEWS: 26 March 2026 We are delighted to
TROG’S 38th ASM puts focus on driving innovative trials
LATEST NEWS: 26 March 2026 TROG’s 2026 Annual Scientific